The benefits of CFTR modulators in treating cystic fibrosis are substantial, significantly improving lung function, reducing pulmonary exacerbations, and enhancing quality of life. However, these benefits must be weighed against the risks of toxic effects. The risk assessment involves understanding the dose-response relationship and identifying the therapeutic window where benefits outweigh potential harms. This balance is crucial for regulatory approval and clinical use.
